ArticlePloS one2026
Computational investigation of African natural products as Helicobacter pylori shikimate kinase inhibitors.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori is one of the most prevalent bacteria, infecting more than 40% of the world's population. Rising antibiotic resistance has created an urgent need for the discovery of novel therapeutic agents. One of the potent drug targets for H. pylori is shikimic acid pathway, which synthesizes chorismate, an essential precursor for various aromatic compounds necessary for the survival of microorganisms. This pathway is absent in humans but its inhibition is lethal to microorganisms. In this study, shikimate kinase, which catalyzes the fifth step of the shikimic acid pathway, was targeted as a receptor. Potential inhibitors were sourced from the North African Natural Product Database (NANPDB) and the East African Natural Product Database (EANPDB). The natural products were investigated using computational tools. Molecular docking was used to screen the natural products and molecular dynamics simulation was used to assess the dynamic stability of docked protein-ligand complexes. The docking protocol was validated by heavy-atom superimposition of the docked shikimate 3-phosphate onto its co-crystallized conformation. Out of approximately 6500 compounds, six compounds with binding energy ranging from -8.73 to -10.57 kcal/mol were selected from molecular docking. Selected compounds showed stability during 200 ns molecular dynamics simulation. These compounds displayed strong prospects for experimental investigation of possible antibiotics against H. pylori.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.